Delivery Order SPE2DB20D3303-SPE2DB25FA2BS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $1,067.73 under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-competitive delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location, serving the federal medical supply chain...
- The Defense Logistics Agency awarded a delivery order valued at $10,244.42 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units). The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,196.74 to AmerisourceBergen Drug Corp for CAPLYTA 21 mg capsules (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $10,226.69. The award was made on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- The Defense Logistics Agency awarded a delivery order valued at $12,137.10 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count units). This firm fixed-price delivery order, which carries no set-aside designation, was competitively awarded and is set for completion by August 4, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations....
- The Defense Logistics Agency awarded a delivery order valued at $1,236.39 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. CAPLYTA is a pharmaceutical treatment for psychiatric conditions, reflecting the company's...
- The Defense Logistics Agency awarded a $11.89K delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). This is a firm fixed price, non-set-aside contract with a completion date of July 24, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder, reflecting the Defense Logistics Agency's ongoing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 10.5 mg capsules (30-count units) with a ceiling value of $2,835.01. This competitive award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the performing location for this order. The award falls under the company's...
- On July 29, 2025, the Defense Logistics Agency awarded a delivery order valued at $7,172.24 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units). This firm fixed price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside competitive award supporting federal medical procurement. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of CAPLYTA 21 mg capsules (30-count units). This firm fixed-price delivery order, valued at $4,321.91, represents a non-set-aside award issued through competitive procurement. The contract is set for ultimate completion on August 8, 2025, with performance taking place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. CAPLYTA...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2BSDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units) valued at $3,348.66 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to be fulfilled at the vendor's Conshohocken, Pennsylvania facility. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's extensive federal portfolio includes a comprehensive range of pharmaceutical products, including brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains. CAPLYTA, an antipsychotic medication used for treating schizophrenia and bipolar disorder, represents a specialized pharmaceutical commodity consistent with the company's role as a primary pharmaceutical supplier to the Defense Health Agency and other federal healthcare systems through the DLA's global pharmaceutical support program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/1/25 |